935534-45-5 Usage
General Description
6-Bromo-2-fluoro-3-methoxy-benzoic acid is a chemical compound with the molecular formula C8H6BrFO3. It is a derivative of benzoic acid, containing a bromine atom at position 6, a fluorine atom at position 2, and a methoxy group at position 3 of the benzene ring. 6-Bromo-2-fluoro-3-methoxy-benzoic acid is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including anti-inflammatory and anticancer properties. The compound's structure and reactivity make it a valuable building block in organic synthesis and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 935534-45-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,5,5,3 and 4 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 935534-45:
(8*9)+(7*3)+(6*5)+(5*5)+(4*3)+(3*4)+(2*4)+(1*5)=185
185 % 10 = 5
So 935534-45-5 is a valid CAS Registry Number.
935534-45-5Relevant articles and documents
PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
-
Paragraph 0765; 0766, (2021/03/19)
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
-
Page/Page column 56, (2018/01/17)
The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activ
ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS
-
Paragraph 0253; 0255, (2015/07/02)
Compounds having an isoindolin-1-one backbone of Formula (I) are disclosed which have utility in treating and/or preventing microbial infections, tumor growth, metastasis and other macrophage migration inhibitory factor (MIF)-modulated pathological condit
